Election 2011 - Party Policies - Health - PHARMAC

Election 2011 - Party Policies - Health - PHARMAC

PHARMAC

Click here to return to the health summary.                   Click here to return to the policy homepage.

  • Create competitive market. (more here)

  • Support the independence of Pharmac.
  • Ensure cost/benefit analyses take into account the full economic cost of ill health, such as unemployment and inability to do unpaid work, when assessing the costs and benefits of a drug.
  • Investigate issues around the patenting of medications including the length of patents and the effect this has on the availability of these medicines to New Zealanders.
  • Ban the 'direct to consumer' advertising of pharmaceuticals, because this practice drives up the demand for pharmaceuticals and plays down adverse reactions to drugs.
  • Set up a register of interests in which pharmaceutical companies are required to disclose annually any gifts/promotions to health professionals, or the health sector.
  • Require health sector organisations and individuals to disclose gifts and funding from pharmaceutical companies.
  • Require the provision of independent health and pharmaceutical information for consumers and clinicians.
  • Monitor and make transparent the promotional activities of pharmaceutical companies to clinicians and health professionals.
  • Ensure members of Pharmac declare any ties to industry or potential conflicts of interests. (more here)

  • Labour will protect and enhance PHARMAC‟s role, including through making protection of PHARMAC a bottom line that will not be traded away in trade negotiations.
  • Labour will not intervene in PHARMAC‟s decisions but will review the criteria for funding highly specialised medicines to ensure that those with rare diseases are treaty equitably and fairly in decisions about the availability of drugs.
  • Labour will continue to ensure that access to HIV retroviral drugs keeps pace with international
    developments. (more here)

  • Support the Pharmac model of affordable medicines and protect it from drug company cartels through unfair trade agreements. (more here)

Not set out on their website.

Not set out on their website.

Not set out on their website.

 

We welcome your help to improve our coverage of this issue. Any examples or experiences to relate? Any links to other news, data or research to shed more light on this? Any insight or views on what might happen next or what should happen next? Any errors to correct?

We welcome your comments below. If you are not already registered, please register to comment.

Remember we welcome robust, respectful and insightful debate. We don't welcome abusive or defamatory comments and will de-register those repeatedly making such comments. Our current comment policy is here.